Researchers Submit Patent Application, "Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (Mcl-1) Protein", for Approval (USPTO 20230357275).
In: Pharma Business Week, 2023-12-01, S. 1829-1829
serialPeriodical
Zugriff:
This document is a patent application for spiro-sulfonamide derivatives that act as inhibitors of the Myeloid Cell Leukemia-1 (Mcl-1) protein. The patent application describes various crystalline forms and pharmaceutically acceptable salts of the compounds, as well as their X-ray powder diffraction patterns and differential scanning calorimetry (DSC) thermograms. The compounds have potential applications in cancer treatment and are designed to induce apoptosis in cancer cells. The patent application provides detailed technical information for researchers interested in studying or developing these compounds. [Extracted from the article]
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (Mcl-1) Protein", for Approval (USPTO 20230357275).
|
---|---|
Zeitschrift: | Pharma Business Week, 2023-12-01, S. 1829-1829 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6675 (print) |
Schlagwort: |
|
Sonstiges: |
|